Near-term applications include combinations with kinase inhibitors (KIs)that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location HOUSTON, TX / ...
OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...
RespireRx Pharmaceuticals Inc. ('RespireRx” or the 'Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...
NEW YORK, NY / ACCESS Newswire / November 14, 2025 / For decades, plastics have moved through the world without an identity. They were manufactured, used, discarded, shredded, melted, and remade, but ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
As drug-resistant infections continue to rise, researchers are looking for new antimicrobial strategies that are both ...
TipRanks on MSN
Celcuity submits gedatolisib new drug application to the FDA
Celcuity (CELC) announced the completion of the submission of its new drug application to the FDA for gedatolisib in hormone receptor positive, ...
A new open-access tool created by University of Toronto Engineering researchers provides a systematic way to organize and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback